SAFC appointed by Curalogic to provide development services
Sigma-Aldrich unit SAFC's Pharma business segment has been appointed by Curalogic A/S, a Danish biotechnology company, to provide protein isolation, extraction and purification services in connection with the development of products focused on Allergic Rhinitis.
Sigma-Aldrich unit SAFC's Pharma business segment has been appointed by Curalogic A/S, a Danish biotechnology company, to provide protein isolation, extraction and purification services in connection with the development of products focused on Allergic Rhinitis.
Curalogic seeks to develop pharmaceuticals that are just as effective as injection immunotherapy and also offer patients the convenience and safety equal to that of the best symptomatic treatments. Key products include a ragweed pollen extract that has just completed clinical Phase II trials, a grass pollen extract and cat extract currently in clinical Phase II, and a house dust mite extract that is in pre-clinical trials.
SAFC Pharma chemists working at the existing St Louis protein purification and extraction facility will begin initial phases of the project. These phases explore development of grass and house dust mite compounds to determine a suitable process for producing sufficient quantities of cGMP material for future clinical trials and commercial launch of these products.
Subsequent phases of the Curalogic project will be transferred into SAFC's new cGMP protein extraction and purification facility after its scheduled completion in April 2007.